CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the −1584G Promoter Polymorphism

This publication has 10 references indexed in Scilit:

• Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black Americans
  Clinical Pharmacology & Therapeutics, 2002
• In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism
  Pharmacogenetics, 2001
• Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
  Pharmacogenetics, 2001
• Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California
  Pharmacogenetics, 2001
• Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6
  Pharmacogenetics, 2000
• Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O‐demethylation in different CYP2D6 genotypes
  British Journal of Clinical Pharmacology, 2000
• Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
  Pharmacogenetics and Genomics, 1999
• CYP2D6 phenotype ??? genotype relationships in African-Americans and Caucasians in Los Angeles
  Pharmacogenetics, 1998
• Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
  Pharmacogenetics, 1998
• Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
  Pharmacogenetics, 1996